BioSyent (CVE:RX) Insider Sells C$21,318.80 in Stock

BioSyent Inc. (CVE:RX) insider Kevin Wilson sold 1,912 shares of the stock in a transaction dated Monday, March 30th. The stock was sold at an average price of C$11.15, for a total transaction of C$21,318.80. Following the sale, the insider owned 61,058 shares of the company’s stock, valued at approximately C$680,796.70. This represents a 3.04% decrease in their ownership of the stock.

BioSyent Stock Up 2.6%

Shares of CVE:RX opened at C$14.80 on Thursday. BioSyent Inc. has a 1 year low of C$9.20 and a 1 year high of C$15.80. The company has a market cap of C$170.16 million, a PE ratio of 18.90 and a beta of 0.93. The company has a debt-to-equity ratio of 2.03, a current ratio of 5.51 and a quick ratio of 6.91. The stock’s 50-day moving average is C$14.64 and its 200 day moving average is C$12.79.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.